FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research note issued to investors on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th. […]
25 Mar 01:16 · The Cerbat Gem